The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial

INTRODUCTION/OBJECTIVES: To evaluate changes in health-related quality of life (HRQoL) and productivity following treatment with intravenous (IV) golimumab in patients with psoriatic arthritis (PsA). METHODS: Patients were randomized to IV golimumab 2 mg/kg (n=241) at Weeks 0, 4, then every 8 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogdie, Alexis, Walsh, Jessica A., Chakravarty, Soumya D., Peterson, Steven, Lo, Kim Hung, Kim, Lilianne, Li, Nan, Hsia, Elizabeth C., Chan, Eric K. H., Kavanaugh, Arthur, Husni, M. Elaine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357705/
https://www.ncbi.nlm.nih.gov/pubmed/33655380
http://dx.doi.org/10.1007/s10067-021-05639-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357705/
https://www.ncbi.nlm.nih.gov/pubmed/33655380
http://dx.doi.org/10.1007/s10067-021-05639-1

Ejemplares similares